98 related articles for article (PubMed ID: 19261952)
1. Evaluation of potential interaction between vinorelbine and clarithromycin.
Yano R; Tani D; Watanabe K; Tsukamoto H; Igarashi T; Nakamura T; Masada M
Ann Pharmacother; 2009 Mar; 43(3):453-8. PubMed ID: 19261952
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
Chen YM; Perng RP; Shih JF; Whang-Peng J
Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
5. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
[TBL] [Abstract][Full Text] [Related]
6. Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer.
Zucali PA; Soto Parra HJ; Cavina R; Campagnoli E; Latteri F; De Vincenzo F; Ceresoli GL; Fazio M; Alloisio M; Santoro A
Oncology; 2006; 71(3-4):229-36. PubMed ID: 17652944
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
[TBL] [Abstract][Full Text] [Related]
9. Severe myelotoxicity in a combination of gefitinib and vinorelbine.
Yoshimura M; Nakamura S; Imamura F; Ueno K; Yamamoto S; Igarashi T
Lung Cancer; 2004 Jul; 45(1):121-3. PubMed ID: 15196742
[No Abstract] [Full Text] [Related]
10. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
Hung IF; Wu AK; Cheng VC; Tang BS; To KW; Yeung CK; Woo PC; Lau SK; Cheung BM; Yuen KY
Clin Infect Dis; 2005 Aug; 41(3):291-300. PubMed ID: 16007523
[TBL] [Abstract][Full Text] [Related]
11. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
12. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Coudert B; Focan C; Genet D; Giacchetti S; Cvickovic F; Zambelli A; Fillet G; Chollet P; Amoroso D; Van Der Auwera J; Lentz MA; Marreaud S; Baron B; Gorlia T; Biville F; Lévi F
Chronobiol Int; 2008 Sep; 25(5):680-96. PubMed ID: 18780198
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
15. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study.
von Plessen C; Strand TE; Wentzel-Larsen T; Omenaas E; Wilking N; Sundstrøm S; Sörenson S
Thorax; 2008 Oct; 63(10):866-71. PubMed ID: 18390631
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin.
Tsuji D; Kamezato M; Daimon T; Taku K; Hatori M; Ikeda M; Hayashi H; Inoue K; Eto T; Itoh K
Chemotherapy; 2013; 59(6):407-13. PubMed ID: 25011542
[TBL] [Abstract][Full Text] [Related]
18. The effects of food on the pharmacokinetic profile of oral vinorelbine.
Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
[TBL] [Abstract][Full Text] [Related]
19. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
[TBL] [Abstract][Full Text] [Related]
20. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
Maione P; Rossi A; Di Maio M; Gridelli C
Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
